Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   4:00:00 PM EDT
747.47
-7.98 (-1.06%)
7:59:32 PM EDT: $745.00 -2.47 (-0.33%)
Products

Dupixent® Approved By FDA As The First And Only Treatment Indicated For Prurigo Nodularis

Published: 09/28/2022 21:51 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Dupixent® (dupilumab) Approved by FDA As the First and Only Treatment Indicated for Prurigo Nodularis.
Regeneron Pharmaceuticals Inc - FDA Evaluated Dupixent Application for Prurigo Nodularis Under Priority Review.